Robert Connelly is President, Chief Executive Officer, and Director of Elicio Therapeutics, Inc. (ELTX). The company reported total compensation of $2,036,441 for fiscal year 2024.
| Salary | $608,400 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $1,093,421 |
| Non-equity incentive plan | $334,620 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $2,036,441 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Elicio Therapeutics, Inc. filed April 9, 2025, accession 0001601485-25-000062.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2024 | President, Chief Executive Officer, and Director | $608,400 | $0 | $0 | $1,093,421 | $334,620 | $0 | $0 | $2,036,441 |
| FY2023 | President, Chief Executive Officer, and Director | $498,750 | $0 | $0 | $0 | $179,550 | $0 | $0 | $678,300 |
Totals as disclosed in each year's own compensation disclosure for Elicio Therapeutics, Inc..
| Named executive officer | Role | FY2024 total |
|---|---|---|
| Robert Connelly this page | President, Chief Executive Officer, and Director | $2,036,441 |
| Christopher Haqq | Executive Vice President, Head of Research and Development and Chief Medical Officer | $926,452 |
| Peter DeMuth | Chief Scientific Officer | $866,671 |
The company's named executive officers for fiscal year 2024, and what it reported for each. See the full Elicio Therapeutics, Inc. compensation brief.
Robert Connelly's compensation sits inside Elicio Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.